Fist author, country, year
|
Setting and participants
|
Intervention and timing
|
outcomes
|
Follow-up (age; completed/enrolled,
n; rate, %)
|
Results
|
Dunstan et al.
Australia,
2003
|
n=98 pregnant, atopic women, were recruited between January 1999 and September 2001 in Western Australia.
|
Fish oil group: fish oil capsules 4×1g/d; 3700mg n-3 LCPUFA (56.0% DHA, and 27.7% EPA)
The control group: olive oil capsule 4×1g /d.
From 20 weeks GA until delivery.
|
Asthma; recurrent wheeze.
|
1year;
83/98;84.7%
|
No difference was seen in the incidence of recurrent wheeze (10/40 vs. 12/43).
No difference was seen in the incidence of asthma (2/40 vs. 6/43).
|
Olsen et al.
Denmark,
2008
|
n=533 Danish pregnant women with singleton pregnancies through antenatal care clinics in 1990.
|
Fish oil capsules, 4×1g/d (32% EPA, 23% DHA).
Control 1: olive oil capsules. Control 2: no oil capsules.
From 30 weeks GA to delivery.
|
Asthma of any types; allergic asthma
|
16 years;
528/533; 99.1%
|
Asthma (any type) was significantly reduced in the fish oil group compared with the olive oil group (8/263 vs. 11/136, P=0.03).
There was a significant effect on allergic asthma (OR,0.27; 95% CI, 0.08-0.91; P=5.03).
|
Furuhjelm et al.,
Sweden,
2011
|
N=145 pregnant women, at risk of having an allergic infant, were recruited through antenatal care clinics in 2003–2005, in Sweden.
|
The -3 group: nine capsules (35% EPA, 1.6 g/day and 25% DHA, 1.1 g/day).
The placebo group:
Nine soya bean oil capsules.
From 25weeks GA to 3.5 months of breastfeeding.
|
Any asthma;
IgE-associated asthma.
|
2years,
143/145;98.6%
|
No difference in the prevalence of any asthma and IgE-associated asthma between the intervention groups (7/54vs.8/65;2/54vs.4/64, respectively; NS).
|
Noakes et al.,
United Kingdom,
2012
|
N=123 pregnant women in the area of Princess Anne Hospital (Southampton, United
Kingdom) were enrolled in the study.
|
The salmon group :2 portions per week of farmed salmon contained 1.14g EPA,
2.32g DHA.
The control group: continue their habitual diet.
From 20 weeks GA until delivery.
|
wheeze.
|
6 months:
86/123;69.9%
|
No significant differences in the incidence of wheeze were observed between the groups (11/46vs.7/37).
|
Palmer et al.,
Australia,
2013
|
N=706 infants, at high hereditary risk of developing allergic
Disease, whose mothers were participating in the DOMInO trial, were recruited from 20th March 2006 and to 8th May 2008, in South Australia.
|
The n-3LCPUFA group:
3×500 mg capsules/d,800mgDHA,100mgEPA.
The control group: 3×500mg vegetable oil capsules.
From 21 weeks GA to birth.
|
IgE-associated asthma
|
3 year:
638/706;90.4%
|
No significant differences were seen in the incidence of IgE-associated asthma (6/368 vs. 14/338).
|
María Consuelo et al.,
Mexico,
2014
|
N=1,094 pregnant women were recruited between February 2005 and February 2007, in Mexico.
586 nonatopic mothers and 283 atopic mothers complete the trial.
|
DHA group: 2capsules/d, contained 400mg DHA/d.
Placebo group: 2capsules/d,
contained a mixture of corn and soy oil.
From 18 to 22 weeks GA to delivery.
|
Wheezing
|
18 months,
869/1094;79.4%
|
No statistically significant protective effect of DHA treatment in the offspring of maternal atopic, compared with the placebo group was observed on the incidence of wheeze (IRR,0.88; 95% CI, 0.64 to 1.21; p=0.42), and the same to the offspring whose mothers are non-atopic (IRR,1.03; 95% CI, 0.83 to 1.27; p=0.80).
|
Berman et al.,
United States,
2016
|
N=118 women,
both with and without
history of allergic disease, were recruited in the United States.
|
Group 1: EPA-rich fish oil (1060 mg EPA plus 274
mg DHA).
Group 2: DHA-rich fish oil (900 mg DHA plus 180 mg EPA).
The placebo: soy oil.
From 12 to 20 weeks GA to delivery.
|
Asthma/wheezing
|
36months
84/118;71.2%
|
No significant differences were seen in the incidence of asthma/wheeze in the offspring between the fish oil group and the placebo group (14/57 vs. 7/27).
|
Best et al.,
Australia,
2016
|
N=706 children,
born to mothers who participated in the (DOMInO) RCT,
with a family history of allergic disease, were recruited in South Australia.
|
The n-3 LCPUFA group:
500 mg fish oil capsules (800mg DHA/d, and 100mgEPA/d).
Control:500mg vegetable oil capsules.
From 21 weeks GA until birth.
|
Wheeze symptoms with sensitization; parent-reported asthma ever
|
6years;
603/706; 85.4%
|
There was no difference between the n-3 LC-PUFA and control groups in the percentage of children with parent-reported asthma(79/367 vs. 73/336).
No significant differences were seen in the incidence of wheeze symptoms with sensitization in the offspring between the groups (60/367 vs. 45/336).
|
Bisgaard et al.,
Denmark,
2016
|
N=736 pregnant women recruited into the Copenhagen Prospective Studies on Asthma in Childhood2010 (COPSAC2010) pregnancy
Cohort, between November 2008 and November 2010.
|
Fish oil capsules, 4×1g/d; 2.4 g/d n−3 LCPUFA (55% EPA and 37% DHA); the control group: olive oil.
From 24 weeks GA until 1 week after delivery.
|
Persistent wheeze or asthma.
|
From birth to date of submission (5–7 yr; mean age, 6.0 yr); not reported.
647/695; 93.1% (5 years)
|
The risk of persistent wheeze or asthma in the treatment group was 19.0% vs. 29.2% in the control group (HR,0.65; 95% CI, 0.47 to 0.91; P = 0.011).
|
Hansen et al.,
Denmark,
2017
|
n=533 Danish pregnant women with singleton pregnancies through antenatal care clinics in 1990.
|
Fish oil capsules, 4×1g/d (32% EPA, 23% DHA).
Control 1: olive oil capsules. Control 2: no oil capsules.
From 30 weeks GA to delivery.
|
Asthma medication used; asthma discharge diagnosis;
allergic asthma.
|
24 years;
522/533; 98.0%
|
Asthma medication prescribed was significantly reduced in the fish oil group compared with the olive oil group (31/262 vs. 28/134; P=0.02).
There was a significant effect on allergic asthma (OR,0.27; 95% CI, 0.08-0.91; P=0.03).
Asthma discharge diagnosis was significantly reduced between groups (8/262 vs. 13/134; P=0.01).
|
GA, gestational age;HDM, house dust mite; LC-PUFA, long chain PUFA; NR, not reported; RCT, randomized controlled trial; NS, no significance, SPT, skin-prick test.
|